The multivisceral landscape of colorectal cancer metastasis: implications for targeted therapies
J Clin Invest. 2024 Mar 1;134(5):e178331. doi: 10.1172/JCI178331.ABSTRACTColorectal cancer (CRC) is among the most common cancer types and the second deadliest malignancy for both sexes. Metastatic disease poses substantial therapeutic challenges, and peritoneal spread, in particular, reduces quality of life and has a dismal outcome. In this issue of the JCI, Berlin and authors have made considerable advancements in understanding the cellular and molecular composition of multivisceral CRC metastasis in a sophisticated murine orthotopic organoid model and in humans. The study provides unprecedented insights into the complex...
Source: Clinical Colorectal Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Dominik Wolf Stefan Salcher Andreas Pircher Source Type: research
NETs unleashed: neutrophil extracellular traps boost chemotherapy against colorectal cancer
This study substantially advances our understanding of the multifaceted role of neutrophils and NETs in the outcome of anticancer treatment.PMID:38426501 | PMC:PMC10904039 | DOI:10.1172/JCI178344 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Alexandra Mousset Jean Albrengues Source Type: research
Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and Colorectal Cancers
J Clin Oncol. 2024 Mar 1:JCO2400019. doi: 10.1200/JCO.24.00019. Online ahead of print.NO ABSTRACTPMID:38427926 | DOI:10.1200/JCO.24.00019 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Julia Butt Meira Epplein Source Type: research
Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort
CONCLUSION: H. pylori positivity may be associated with small but statistically significant higher CRC incidence and mortality; untreated individuals, especially those with confirmed active infection, appear to be most at risk.PMID:38427927 | DOI:10.1200/JCO.23.00703 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Shailja C Shah M Constanza Camargo Mark Lamm Ranier Bustamante Christianne L Roumie Otis Wilson Alese E Halvorson Robert Greevy Lin Liu Samir Gupta Joshua Demb Source Type: research
The multivisceral landscape of colorectal cancer metastasis: implications for targeted therapies
J Clin Invest. 2024 Mar 1;134(5):e178331. doi: 10.1172/JCI178331.ABSTRACTColorectal cancer (CRC) is among the most common cancer types and the second deadliest malignancy for both sexes. Metastatic disease poses substantial therapeutic challenges, and peritoneal spread, in particular, reduces quality of life and has a dismal outcome. In this issue of the JCI, Berlin and authors have made considerable advancements in understanding the cellular and molecular composition of multivisceral CRC metastasis in a sophisticated murine orthotopic organoid model and in humans. The study provides unprecedented insights into the complex...
Source: Clinical Colorectal Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Dominik Wolf Stefan Salcher Andreas Pircher Source Type: research
NETs unleashed: neutrophil extracellular traps boost chemotherapy against colorectal cancer
This study substantially advances our understanding of the multifaceted role of neutrophils and NETs in the outcome of anticancer treatment.PMID:38426501 | DOI:10.1172/JCI178344 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Alexandra Mousset Jean Albrengues Source Type: research
Potent Tool: Helicobacter pylori Treatment to Reduce the Risk of Both Gastric and Colorectal Cancers
J Clin Oncol. 2024 Mar 1:JCO2400019. doi: 10.1200/JCO.24.00019. Online ahead of print.NO ABSTRACTPMID:38427926 | DOI:10.1200/JCO.24.00019 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Julia Butt Meira Epplein Source Type: research
Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort
CONCLUSION: H. pylori positivity may be associated with small but statistically significant higher CRC incidence and mortality; untreated individuals, especially those with confirmed active infection, appear to be most at risk.PMID:38427927 | DOI:10.1200/JCO.23.00703 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Shailja C Shah M Constanza Camargo Mark Lamm Ranier Bustamante Christianne L Roumie Otis Wilson Alese E Halvorson Robert Greevy Lin Liu Samir Gupta Joshua Demb Source Type: research
Improved risk stratification scheme for mismatch repair proficient stage II colorectal cancers using the digital pathology biomarker QuantCRC
CONCLUSIONS: Incorporation of QuantCRC into risk stratification provides a powerful predictor of RFS that has potential to guide subsequent treatment and surveillance for stage II MMRP CRCs.PMID:38421684 | DOI:10.1158/1078-0432.CCR-23-3211 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Christina Wu Reetesh K Pai Heidi Kosiorek Imon Banerjee Ashlyn Pfeiffer Catherine E Hagen Christopher P Hartley Rondell P Graham Mohamad B Sonbol Tanios Bekaii-Saab Hao Xie Frank A Sinicrope Bhavik Patel Thomas Westerling-Bui Sameer Shivji James Conner Ca Source Type: research
Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance models
J Clin Invest. 2024 Feb 29:e161941. doi: 10.1172/JCI161941. Online ahead of print.ABSTRACTRAD54 and BLM helicase play pivotal roles during homologous recombination repair (HRR) ensuring genome maintenance. BLM amino acids (181-212) interacts with RAD54 and enhances its chromatin remodelling activity. Functionally, this interaction heightens HRR, leading to a decrease in residual DNA damage in colon cancer cells. This contributes to chemoresistance in colon cancer cells against cisplatin, camptothecin and oxaliplatin, eventually promoting tumorigenesis in preclinical colon cancer mouse models. ChIP-seq analysis and validati...
Source: Clinical Colorectal Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Ekjot Kaur Ritu Agrawal Rimpy Arun Vinoth Madhavan Vivek Srivastava Dilip Kumar Pragyan Parimita Rath Nitin Kumar Sreekanth Vedagopuram Nishant Pandey Swati Priya Patrick Legembre Samudrala Gourinath Avinash Bajaj Sagar Sengupta Source Type: research
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration
CONCLUSION: The results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03864042, registered 6 March 2019.PMID:38424308 | DOI:10.1007/s40262-024-01352-9 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Joseph Piscitelli Micaela B Reddy Lance Wollenberg Laurence Del Frari Jason Gong Linda Wood Yizhong Zhang Kyle Matschke Jason H Williams Source Type: research
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors
In this study we investigate the effectiveness of inhibiting JAK/STAT3 in diverse CRC models, establish in which contexts high pathway expression is prognostic and perform in depth analysis underlying phenotypes. In this study we investigated the use of JAK inhibitors for anti-cancer activity in CRC cell lines, mouse model organoids and patient-derived organoids. Immunohistochemical staining of the TransSCOT clinical trial cohort, and 2 independent large retrospective CRC patient cohorts was performed to assess the prognostic value of JAK/STAT3 expression. We performed mutational profiling, bulk RNASeq and NanoString GeoMx...
Source: Clinical Colorectal Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Kathryn A F Pennel Phimmada Hatthakarnkul Colin S Wood Guang-Yu Lian Sara S F Al-Badran Jean A Quinn Assya Legrini Jitwadee Inthagard Peter G Alexander Hester van Wyk Ahmad Kurniawan Umar Hashmi Michael A Gillespie Megan Mills Aula Ammar Jennifer Hay Ditt Source Type: research
Improved risk stratification scheme for mismatch repair proficient stage II colorectal cancers using the digital pathology biomarker QuantCRC
CONCLUSIONS: Incorporation of QuantCRC into risk stratification provides a powerful predictor of RFS that has potential to guide subsequent treatment and surveillance for stage II MMRP CRCs.PMID:38421684 | DOI:10.1158/1078-0432.CCR-23-3211 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Christina Wu Reetesh K Pai Heidi Kosiorek Imon Banerjee Ashlyn Pfeiffer Catherine E Hagen Christopher P Hartley Rondell P Graham Mohamad B Sonbol Tanios Bekaii-Saab Hao Xie Frank A Sinicrope Bhavik Patel Thomas Westerling-Bui Sameer Shivji James Conner Ca Source Type: research
Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response
CONCLUSIONS: Our study emphasizes the critical impact of the screening methods for determining correlation between PDO drug screens and mCRC patient outcomes. Our 5-step optimization strategy provides a basis for future research on the clinical utility of PDO screens.PMID:38414064 | DOI:10.1186/s13046-024-02980-6 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 28, 2024 Category: Cancer & Oncology Authors: Lidwien P Smabers Emerens Wensink Carla S Verissimo Esmee Koedoot Katerina-Chara Pitsa Maarten A Huismans Celia Higuera Bar ón Mayke Doorn Liselot B Valkenburg-van Iersel Geert A Cirkel Anneta Brousali Ren é Overmeer Miriam Koopman Manon N Braat Bas Pen Source Type: research
Value of glucose transport protein 1 expression in detecting lymph node metastasis in patients with colorectal cancer
CONCLUSION: GLUT-1 expression was significantly correlated with the SUVmax of 18F-FDG-PET/CT for primary tumors and lymph nodes. Clinicians should consider GLUT-1 expression in preoperative endoscopic biopsy in interpreting PET/CT findings.PMID:38414613 | PMC:PMC10895641 | DOI:10.12998/wjcc.v12.i5.931 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 28, 2024 Category: Cancer & Oncology Authors: Hongsik Kim Song-Yi Choi Tae-Young Heo Kyeong-Rok Kim Jisun Lee Min Young Yoo Taek-Gu Lee Joung-Ho Han Source Type: research
